Compass Wealth Management LLC Buys Shares of 5,373 Revvity Inc. $RVTY

Compass Wealth Management LLC purchased a new position in Revvity Inc. (NYSE:RVTY) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,373 shares of the company’s stock, valued at approximately $598,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in RVTY. Ascentis Independent Advisors bought a new stake in shares of Revvity during the 1st quarter worth $29,000. CYBER HORNET ETFs LLC purchased a new position in Revvity in the second quarter worth $32,000. MUFG Securities EMEA plc bought a new position in Revvity in the second quarter valued at $34,000. SJS Investment Consulting Inc. increased its stake in Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after acquiring an additional 521 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Revvity during the second quarter valued at about $49,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Stock Down 1.9%

Shares of NYSE RVTY opened at $113.99 on Wednesday. The firm’s fifty day moving average is $110.13 and its 200 day moving average is $100.02. Revvity Inc. has a 52 week low of $81.22 and a 52 week high of $118.34. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The company has a market cap of $12.72 billion, a price-to-earnings ratio of 54.28, a PEG ratio of 2.13 and a beta of 1.07.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.20. The business had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts expect that Revvity Inc. will post 5.36 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s dividend payout ratio is 13.33%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on RVTY shares. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a report on Sunday. JPMorgan Chase & Co. decreased their price objective on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. TD Cowen restated a “buy” rating on shares of Revvity in a research report on Wednesday, July 15th. Finally, Stifel Nicolaus cut their target price on Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $108.36.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.